Lisa M. Dunkle

4.2k total citations
75 papers, 2.5k citations indexed

About

Lisa M. Dunkle is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Lisa M. Dunkle has authored 75 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Infectious Diseases, 32 papers in Epidemiology and 18 papers in Virology. Recurrent topics in Lisa M. Dunkle's work include HIV/AIDS drug development and treatment (19 papers), HIV Research and Treatment (17 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). Lisa M. Dunkle is often cited by papers focused on HIV/AIDS drug development and treatment (19 papers), HIV Research and Treatment (17 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). Lisa M. Dunkle collaborates with scholars based in United States, Germany and United Kingdom. Lisa M. Dunkle's co-authors include Ruvim Izikson, Ralph D. Feigin, Manon Cox, P. Patriarca, Karen L. Goldenthal, Richard J. Whitley, Shehla H. Naqvi, Michael L. Wong, Thomas Brotherton and Barbara W. Stechenberg and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and PEDIATRICS.

In The Last Decade

Lisa M. Dunkle

71 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa M. Dunkle United States 29 1.2k 1.2k 642 267 244 75 2.5k
G. P. Melcher United States 24 769 0.6× 1.1k 1.0× 763 1.2× 178 0.7× 242 1.0× 38 2.1k
Norman Markowitz United States 23 1.2k 0.9× 1.7k 1.4× 620 1.0× 242 0.9× 160 0.7× 65 2.8k
Carmen Quereda Spain 32 1.8k 1.5× 1.6k 1.4× 460 0.7× 245 0.9× 192 0.8× 132 3.4k
Chris Birch Australia 30 1.2k 1.0× 1.7k 1.4× 761 1.2× 172 0.6× 300 1.2× 61 3.0k
Sibyl P. M. Geelen Netherlands 28 553 0.4× 1.0k 0.9× 664 1.0× 165 0.6× 166 0.7× 59 1.9k
Alison Kesson Australia 32 1.4k 1.1× 1.1k 1.0× 326 0.5× 698 2.6× 178 0.7× 115 2.7k
Richard L. Hodinka United States 36 1.8k 1.4× 1.5k 1.3× 251 0.4× 206 0.8× 450 1.8× 108 3.7k
Khuanchai Supparatpinyo Thailand 30 2.1k 1.7× 2.3k 1.9× 631 1.0× 343 1.3× 175 0.7× 91 3.2k
A Goudeau France 36 3.1k 2.5× 1.0k 0.9× 511 0.8× 401 1.5× 515 2.1× 177 4.9k
Richard B. Markham United States 28 686 0.5× 1.1k 1.0× 1.2k 1.8× 189 0.7× 545 2.2× 85 2.7k

Countries citing papers authored by Lisa M. Dunkle

Since Specialization
Citations

This map shows the geographic impact of Lisa M. Dunkle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa M. Dunkle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa M. Dunkle more than expected).

Fields of papers citing papers by Lisa M. Dunkle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa M. Dunkle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa M. Dunkle. The network helps show where Lisa M. Dunkle may publish in the future.

Co-authorship network of co-authors of Lisa M. Dunkle

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa M. Dunkle. A scholar is included among the top collaborators of Lisa M. Dunkle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa M. Dunkle. Lisa M. Dunkle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kalkeri, Raj, Mingzhu Zhu, Anand Parekh, et al.. (2025). Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform–specific priming and immune imprinting. Journal of Infection. 91(2). 106543–106543. 1 indexed citations
2.
3.
Follmann, Dean, Allyson Mateja, Michael P. Fay, et al.. (2024). Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine. Clinical Infectious Diseases. 79(1). 78–85. 3 indexed citations
4.
Davis, Matthew, Jeffrey Adelglass, Gordon Chau, et al.. (2023). Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults. Vaccine. 41(41). 5965–5973. 5 indexed citations
5.
6.
Dunkle, Lisa M., Ruvim Izikson, P. Patriarca, et al.. (2017). Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older. New England Journal of Medicine. 376(25). 2427–2436. 180 indexed citations
7.
Dunkle, Lisa M., Ruvim Izikson, P. Patriarca, et al.. (2017). Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age. The Journal of Infectious Diseases. 216(10). 1219–1226. 37 indexed citations
8.
Izikson, Ruvim, David J. Leffell, S. Allan Bock, et al.. (2015). Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age. Vaccine. 33(48). 6622–6628. 20 indexed citations
9.
10.
Caseiro, Marcos Montani, Mark Nelson, Ricardo Sobhie Diaz, et al.. (2012). Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials. Journal of Infection. 65(4). 326–335. 33 indexed citations
11.
Suleiman, Jamal, Barry S. Zingman, Ricardo Sobhie Diaz, et al.. (2010). Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment‐Experienced Subjects: 48‐Week Results of the VICTOR‐E1 Phase 2 Trial. The Journal of Infectious Diseases. 201(4). 590–599. 37 indexed citations
12.
Kelleher, Thomas, Anne Cross, & Lisa M. Dunkle. (1999). Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. Clinical Therapeutics. 21(7). 1182–1192. 30 indexed citations
13.
Pollard, Richard B., Dolores M. Peterson, David J. Hardy, et al.. (1999). Safety and Antiretroviral Effects of Combined Didanosine and Stavudine Therapy in HIV-Infected Individuals With CD4 Counts of 200 to 500 cells/mm3. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 22(1). 39–39. 23 indexed citations
14.
Elion, Richard, Sanjeev Kaul, Catherine Knupp, et al.. (1999). The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection. Clinical Therapeutics. 21(11). 1853–1863. 3 indexed citations
15.
Petersen, E. A., C H Ramírez-Ronda, William D. Hardy, et al.. (1995). Dose-Related Activity Of Stavudine In Patients Infected With Human Immunodeficiency Virus. The Journal of Infectious Diseases. 171(Supplement 2). S131–S139. 48 indexed citations
16.
Murray, Henry W., K. Squires, Wolfgang Weiß, et al.. (1995). Stavudine In Patients With Aids And Aids-Related Complex: Aids Clinical Trials Group 089. The Journal of Infectious Diseases. 171(Supplement 2). S123–S130. 42 indexed citations
17.
Grasela, Thaddeus H., Mohan Beltangady, C A Knupp, et al.. (1994). Analysis of Potential Risk Factors Associated with the Development of Pancreatitis in Phase I Patients with AIDS or AIDS-Related Complex Receiving Didanosine. The Journal of Infectious Diseases. 169(6). 1250–1255. 21 indexed citations
18.
Balfour, Henry H., Harley A. Rotbart, Sandor Feldman, et al.. (1992). Acyclovir treatment of varicella in otherwise healthy adolescents. The Journal of Pediatrics. 120(4). 627–633. 108 indexed citations
19.
Martin, John C., Michael J. M. Hitchcock, Arnold Fridland, et al.. (1990). Comparative Studies of 2′,3′‐Didehydro‐2′,3′‐Dideoxythymidine (D4T) with other Pyrimidine Nucleoside Analogues. Annals of the New York Academy of Sciences. 616(1). 22–28. 17 indexed citations
20.
Whitley, Richard J., Lawrence Corey, Ann M. Arvin, et al.. (1988). Changing Presentation of Herpes Simplex Virus Infection in Neonates. The Journal of Infectious Diseases. 158(1). 109–116. 214 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. P. Melcher Breakdown of academic impact, for papers by Norman Markowitz Breakdown of academic impact, for papers by Carmen Quereda Breakdown of academic impact, for papers by Chris Birch Breakdown of academic impact, for papers by Sibyl P. M. Geelen Breakdown of academic impact, for papers by Alison Kesson Breakdown of academic impact, for papers by Richard L. Hodinka Breakdown of academic impact, for papers by Khuanchai Supparatpinyo Breakdown of academic impact, for papers by A Goudeau Breakdown of academic impact, for papers by Richard B. Markham
Rankless by CCL
2026